Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

Figure 3

Changes in serum tumor marker levels during the study in case 1 (A: CEA, B: CA19-9). Levels of CEA and CA19-9 were 15.9 ng/ml and 152.4 U/ml, respectively before vaccination. Levels decreased continuously until the 4th or 5th vaccination to 6.5 ng/ml and 64.2 U/ml, respectively. However, they increased to 16.2 ng/ml and 128.9 U/ml respectively after 6th vaccination. Arrows indicate the times of vaccination.

Back to article page